1. P330 Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD. (27th May 2021) Authors: Derikx, L; Dolby, H; Plevris, N; Lucaciu, L; Rees, C; Lyons, M; Siakavellas, S; Constantine-Cooke, N; Noble, C; O'Hare, C; Merchant, L; Arnott, I; Jones, G R; Lees, C Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗